APA (7th ed.) Citation

Koya, D., Fujii, M., Kitada, M., Tsuda, S., Konishi, K., Takeda-Watanabe, A., . . . Nakagawa, A. Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner. BMJ Publishing Group.

Chicago Style (17th ed.) Citation

Koya, Daisuke, Mizue Fujii, Munehiro Kitada, Shin-ichi Tsuda, Kazunori Konishi, Ai Takeda-Watanabe, Keizo Kanasaki, Makoto Nishizawa, and Atsushi Nakagawa. Anagliptin Ameliorates Albuminuria and Urinary Liver-type Fatty Acid-binding Protein Excretion in Patients with Type 2 Diabetes with Nephropathy in a Glucose-lowering-independent Manner. BMJ Publishing Group.

MLA (9th ed.) Citation

Koya, Daisuke, et al. Anagliptin Ameliorates Albuminuria and Urinary Liver-type Fatty Acid-binding Protein Excretion in Patients with Type 2 Diabetes with Nephropathy in a Glucose-lowering-independent Manner. BMJ Publishing Group.